Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.